photo walkheader_zpsd5bunpmi.png

Category Archives: Pancreatic Cancer Medical Treatment

Modified Irinotecan for Multi-drug Treatment of Pancreatic Cancer – an Update

More than a year ago (10/22/15), the U.S. Food and Drug Administration approved a modified form of the FOLFIRINOX regimen as a second line treatment for patients with metastatic pancreatic cancer (ductal adenocarcinoma of the pancreas) whose gemcitabine-based therapy had failed.  We reported this development Here. The modified FDA-approved regimen was different from the “standard” […]

2016 ASCO Practice Guidelines for Advanced Pancreatic Cancer

2016 ASCO PRACTICE GUIDELINES FOR ADVANCED ADENOCARCINOMA OF THE PANCREAS Davendra P.S. Sohal, Pamela B. Mangu, Alok A. Khorana, Manish A. Shah, Philip A. Philip, Eileen M. O’Reilly, Hope E. Uronis, Ramesh K. Ramanathan, Christopher H. Crane, Anitra Engebretson, Joseph T. Ruggiero, Mehmet S. Copur, Michelle Lau, Susan Urba and Daniel Laheru   Abstract Purpose: […]

“Modified” FOLFIRINOX Regimen Approved by FDA for 2nd Line Treatment of Pancreatic Cancer

On the 22nd of October, 2015, the U.S. Food and Drug Administration approved a new combination therapy that includes the drug Onivyde for patients with metastatic pancreatic cancer (ductal adenocarcinoma of the pancreas) who had earlier been treated until progression of disease while on gemcitabine or a gemcitabine-based regimen. Onivyde is liposomal irinotecan, a topoisomerase I […]

Page 3 of 1112345...10...Last »